Recent investigations have focused on the intersection of GLP-1|GIP|GCGR agonist therapies and dopaminergic communication. While GLP agonists are widely employed for addressing type 2 diabetes, their emerging impacts on reward circuits, specifically influenced by DA pathways, are receiving significant attention. This paper provides a summary assess